Global Lumakras Drug Market By Therapy Type, Disease Indication, and Region (Including COVID-19 Impact Analysis): A Report by Absolute Markets Insights – Yahoo Finance

PUNE, India, March 14, 2022 /PRNewswire/ — The growing cancer burden and rising cancer mortality rates indicate an unmet need for the development of novel cancer therapies. Significant investments towards advances in cancer therapeutics is boosting the growth of lumakras drug market. LUMAKRAS is a prescription medication used to treat non-small cell lung cancer (NSCLC) in adults, which has spread to other parts of the body or that surgery cannot remove, and whose tumor has an abnormal KRAS G12C gene. Increased efforts by major key companies to develop advanced lumakras drugs are expected to drive the growth of lumakras drug market during the forecast period. For instance, Revolution Medicines, Inc., a clinical-stage oncology organization evolving novel targeted therapies for RAS-addicted cancers, announced the first patient dose in a worldwide Phase 2 study evaluating the combination of RMC-4630 and Lumakras (sotorasib) in patients with advanced non-small-cell lung cancer. RMC-4630 is a highly effective, oral, and selective inhibitor of the SHP2 protein.
Get PDF sample report with all related graphs & charts (pre and post covid-19 impact analysis): https://www.absolutemarketsinsights.com/request_sample.php?id=1089
How Absolute Market Insights is unique in nature?
The research report on Lumakras Drug Market will include extensive information based on the following pointers:
Global Market size and forecast values (2021 – 2030), in terms of revenue (US$ Million) by segments/sub-segments.
Split of the market revenue (US$ Million) into all the relevant segments & sub-segments across all major regions/countries.
Market Determinants and Influencing Factors
Macro-Economic and Micro-Economic Indicators
Market Dynamic
Trends on Global Lumakras Drug Market
Exclusive Details on the Effect of the Pandemic
Porter's Five Forces Analysis
Competitor Landscape
The final report will include competitive product benchmarking which will encompass comparison of varied services offered by different market participants on the basis of their features and capabilities that will help you to understand their market offerings. Furthermore, for each company, we will provide information regarding company details, company overview, product offerings, key developments, financial analysis, and SWOT analysis and business strategies.
The research study specific to a region, including North America, Europe, Asia Pacific, Middle East & Africa and Latin America, is also available.
We offer our reports in different languages which include German, Chinese, French, Russian, Spanish, Arabic, Japanese, and Korean amongst others.
Speak to our analyst in case of queries before buying this report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1089
The Combination Therapy segment in the Global Lumakras Drug Market to witness significant growth over the Forecast Period
Globally increasing cancer cases are expected to drive the growth of combination therapy segment in the global lumakras drug market over the forecast period. A cornerstone of cancer therapy is combination therapy, a treatment modality that combines two or more therapeutic agents. The combination of anti-cancer drugs improves efficacy when compared to monotherapy because it targets key pathways in a synergistic or additive manner. Early-stage lung cancer is frequently treated with a combination of two chemotherapy drugs.
In May 2021, Amgen announced the receipt of FDA approval on LUMAKRAS (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This is the first FDA-approved targeted therapy for tumors with any KRAS mutation, which accounts for approximately 25% of non-small cell lung cancer mutations. KRAS G12C mutations account for approximately 13% of non-small cell lung cancer mutations. LUMAKRAS was the first KRASG12C inhibitor to enter clinical trials, and is currently being studied in the largest clinical programme, which includes 11 combinations and global investigator sites on five continents.
Metastatic Non-Small Cell Lung Cancer (NSCLC) is expected to be one of the Significant Segments over the Forecast Period
Non-small cell lung cancer (NSCLC) is any epithelial lung cancer other than small cell lung cancer (SCLC). Cigarette smoking has been identified as a major risk factor for developing NSCLC, along with other environmental and genetic risk factors. Non-small cell lung cancer (NSCLC) has been identified as the most common type of lung cancer. Metastatic NSCLC occurs when NSCLC spreads to other parts of the body. Treatment for metastatic NSCLC is frequently aimed at alleviating symptoms and extending life expectancy. At the time of diagnosis, approximately 30–40% of NSCLC patients have metastatic disease. According to the American Cancer Society (ACS), NSCLC accounts for approximately 80 to 85 percent of all cases. A growing population, in both developed and developing regions, susceptible to the aforementioned risk factors is a major factor driving segment growth during the forecast period.
View our exclusive press releases on Industry Global News24
Impact of COVID-19 on the Global Lumakras Drug Market
In March 2020, the World Health Organization (WHO) declared the novel coronavirus disease (COVID-19), caused by the coronavirus 2 a pandemic that caused severe acute respiratory syndrome (SARS-CoV-2). When COVID-19 cases began to rise around the world, experts determined the virus was exceptionally dangerous for patients suffering from heart disease and other cancer-related serious diseases. Many healthcare professionals' adapted short-term changes in cancer care delivery, such as temporarily discontinuing non-emergent cancer screenings, shifting care delivery to telemedicine, and postponing procedures. However, post the relaxation of stringent lockdown measures, companies in the lumakras drug market are working profusely on research and development activities. Similar efforts by companies to adapt more seamlessly to changing market conditions suggest that the global lumakras drug market will grow positively during the forecast period.
Asia Pacific to register Highest Growth Rate in the Global Lumakras Drug Market over the Forecast Period
Asia Pacific region is expected to grow at the fastest rate in the global lumakras drug market over the forecast period. Rising cancer cases along with increased investment and funding in drug research and development in the region are all contributing to the region's growth in the global market. After U.S., Amgen received approval for LUMAKRAS (sotorasib) in Japan in January 2022. The drug has been approved for the treatment of KRAS G12C-mutated advanced and/or recurrent non-small cell lung cancer, which has progressed after systemic anticancer therapy. Furthermore, in the healthcare sector, countries such as China, India, and Japan are increasingly investing towards enhancement of healthcare infrastructure, which is significantly aiding the market growth.
Purchase the latest in-depth Lumakras Drug Market report: https://www.absolutemarketsinsights.com/checkout?id=1089
The key market participants operating in the global lumakras drug market are:
Amgen Inc.
Boehringer Ingelheim
Eli Lilly and Company
Mirati Therapeutics, Inc.
Moderna, Inc.
Oblique Therapeutics AB
Revolution Medicines, Inc.
Silenseed LTD
Other Market Participants
Global Lumakras Drug Market
By Therapy Type
By Disease Indication
By Region
Browse more trending reports by Absolute Markets Insights:
Oncology Pharmaceuticals Market – Global oncology pharmaceuticals market is anticipated to clock a CAGR of 11.9% over the forecast period
T-Cell Therapy Market – Global T-cell therapy market is anticipated to grow at a CAGR of 12.45% over the forecast period.
Metastatic Colorectal Cancer Market – Global metastatic colorectal cancer market is estimated to register a CAGR of 9.81% over the forecast period
Radiopharmaceutical Theragnostic Market – Global radiopharmaceutical theragnostic market was valued at US$ 1123.42 Mn in 2020 and is projected to clock a CAGR of 15.83% over the forecast period.
Melphalan Market – Global melphalan market generated a revenue of US$ 137.85 Mn in 2019 and is estimated to grow at a CAGR of 4.4% over the forecast period and reach US$ 203.73 Mn by 2028.
Brachytherapy Seeds MarketNorth America, Europe and Asia Pacific brachytherapy seeds market was valued at US$ 26,647.7 Mn in 2020 and is expected to reach US$ 60,680.5 Mn by 2028, growing at a CAGR of 8.7% over the forecast period.
Oncology Market – Global oncology market, in terms of revenue, was valued at US$ 93.60 Bn in 2016 and is projected to reach US$ 127.52 Bn by 2021 over the forecast period.
Glance through Absolute Markets Insights plethora of reports on Healthcare Category
About Us:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Us:
Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: IN +91-7400-24-24-24, US +1-510-420-1213
Website: www.absolutemarketsinsights.com
View original content:https://www.prnewswire.com/news-releases/global-lumakras-drug-market-by-therapy-type-disease-indication-and-region-including-covid-19-impact-analysis-a-report-by-absolute-markets-insights-301501939.html
SOURCE Absolute Markets Insights
The U.S. government may throw its weight (and its money) behind expanding lithium production tomorrow.
Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk posted in a Twitter thread on Monday advising followers to own “physical things” when inflation is high. In the tweet, Musk said “As a general principle, for those looking for advice from this thread, it is generally better to own physical things like a home or stock in companies you think make good products, than dollars when inflation is high. I still own & won’t sell my Bitcoin, Ethereum or Doge fwiw.” The biggest takeaway for some followers seems to ha
Shares of AMC Entertainment Holdings (NYSE: AMC) look like they're about to break their winning streak as shares are down 6.1% at 1:22 p.m. ET. Of course, it looked that way yesterday, too, as the stock had stumbled out of the gate and trading in its shares were halted by the New York Stock Exchange after it triggered a circuit breaker. Once trading resumed, AMC's stock quickly reversed course and it ended the day $0.11 per share higher.
Even with the economic reopening, the home improvement retailer's fundamentals are still robust.
There was no bad news for Nvidia specifically — but the good news wasn't all that great. Take semiconductors peer company Micron (NASDAQ: MU) for example. Micron reported a big earnings beat for its second quarter of fiscal 2022 last night, and guided investors to expect another beat in the third quarter.
What happened Shares of Vir Biotechnology (NASDAQ: VIR) were skyrocketing 19.4% higher as of 12:33 p.m. ET on Wednesday. The big jump came after S&P Global announced that Vir will replace Matador Resources on the S&P SmallCap 600 index effective before the market open on April 4.
Nreal touts its glasses as being able to project a 'portable IMAX' theater-sized screen in front of users.
Vyant Bio, located in Cherry Hill, was created one year ago following the merger of Cancer Genetics and StemoniX.
Americans may have more help in the fight to save for retirement after House passes bipartisan retirement legislation.
The best dividend stocks have a long history of steadily increasing their payments. The top tiers are Dividend Aristocrats and Dividend Kings, companies that have delivered steady dividend growth for 25 and 50 years, respectively. Three of these up-and-comers are Brookfield Infrastructure (NYSE: BIPC)(NYSE: BIP), Brookfield Renewable (NYSE: BEPC)(NYSE: BEP), and Enterprise Products Partners (NYSE: EPD).
Advisors Capital Management Partner and Portfolio Manager JoAnne Feeney joins Yahoo Finance Live to discuss market risks and geopolitical uncertainty as well as defense and homebuilder stock picks.
Cathie Wood's Ark bought and sold shares of electric-vehicle makers and snapped up shares of two biotech companies.
(Bloomberg) — The 11% surge in U.S. stocks in the past two weeks has the hallmarks of a bear-market rally that might give way to deeper losses.Most Read from BloombergUkraine Update: U.S. Doubts Russian Pullback; Lavrov in ChinaUkraine Update: Kyiv Seeks Cease-Fire Deal in Russia TalksHome Prices Suggest Housing Bubble Brewing in U.S., Dallas Fed SaysThe Fed Has Made a U.S. Recession InevitableWorld’s Longest Passenger Flight Plans to Avoid Russian SkiesThat’s the conclusion of analysts at Bank
Apple's stock has been rocking of late. Here's why.
Find out how much of the global non-alcoholic beverage industry is controlled by the two major companies, Coca-Cola and Pepsi.
Yahoo Finance Live's Brad Smith looks at Chewy's Q4 earnings and revenue miss.
Automotive giant Ford Motor Company (NYSE: F) stock has had a rough start to 2022, losing 18.5% of its value since the start of the year. On Tuesday, however, Ford finally found the gas pedal — and floored it. As of 11 a.m. ET, Ford stock is up a solid 6.6%.
Overseas shipments of shale gas are replacing Russian supplies in Europe and boosting prices at home.
Oil has been one of the most volatile assets since the Russian invasion of Ukraine as traders balance the impact of sanctions with both the likelihood of increased production elsewhere and the possibility that high prices would knock demand.
(Bloomberg) — The number of empty liquefied natural gas tankers outside one of the world’s biggest exporters of the fuel has risen to the highest in almost a year, exacerbating a global shortage. Most Read from BloombergUkraine Update: U.S. Doubts Russian Pullback; Lavrov in ChinaHome Prices Suggest Housing Bubble Brewing in U.S., Dallas Fed SaysUkraine Update: Kyiv Seeks Cease-Fire Deal in Russia TalksThe Fed Has Made a U.S. Recession InevitableHackers Steal About $600 Million in One of the Bi

source

Leave a Comment

Your email address will not be published.

Shopping Cart